Bioidentical hormones for women with vasomotor symptoms

Cochrane Database of Systematic Reviews

Volumn 2016, Issue 8, 2016, Pages

  Gaudard, Ana Marcia I S ^a   Silva de Souza, Sulani ^a   Puga, Maria E S ^b   Marjoribanks, Jane ^c   da Silva, Edina M K ^d   Torloni, Maria R ^b  

^a School of Sciences of Health FEPECS   (Brazil)

^b Brazilian Cochrane Center   (Brazil)

^c UNIVERSITY OF AUCKLAND   (New Zealand)

^d FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

CONJUGATED ESTROGEN; ESTRADIOL; ESTROGEN;

BREAST TENDERNESS; DRUG EFFICACY; DRUG SAFETY; FEMALE; HEADACHE; HORMONAL THERAPY; HOT FLUSH; HUMAN; OUTCOME ASSESSMENT; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SKIN MANIFESTATION; SYMPTOMATOLOGY; SYSTEMATIC REVIEW; VAGINA BLEEDING; VASOMOTOR DISORDER; HOT FLASHES; META ANALYSIS;

ESTRADIOL; ESTROGENS; ESTROGENS, CONJUGATED (USP); FEMALE; HOT FLASHES; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84979999684     PISSN: None     EISSN: 1469493X     Source Type: Journal    
DOI: 10.1002/14651858.CD010407.pub2     Document Type: Review

References (113)

1. Archer DR, Fischer LA, Rich D, Schade GH, Schwartz S, Wittcoff H, et al. Estrace vs Premarin for treatment of menopausal symptoms: dosage comparison study. Advances in Therapy 1992;9:21-31.
2. Archer DF. Percutaneous 17-estradiol gel for the treatment of vasomotor symptoms in postmenopausal women. The Journal of The North American Menopause Society 2003;10(6):516-21. [DOI: 10.1097/01]
3. Archer DF, Pickar JH, MacAllister DC, Warren MP. Transdermal estradiol gel for the treatment of symptomatic postmenopausal women. Menopause 2012;19(6):622-9.
4. Bacchi-Modena A, Bacchi-Modena C, Bolis P, Campagnoli M, De Cicco R, Meschia G, et al. Efficacy and tolerability of Estraderm MX, a new estradiol matrix patch. Maturitas 1997;27:285-92.
5. Buster JE, Koltun WD, Pascual ML, Day WW, Peterson C. Low-dose estradiol spray to treat vasomotor symptoms. Obstetrics and Gynecology 2008;111:1343-51. [CENTRAL: CN-00640015; ]
6. Cohen L, Coxwell WL, Melchione T, Koltun W, Gibson E, Gupta N, et al. Low-dose 17-beta estradiol matrix transdermal system in the treatment of moderate-to-severe hot flushes in postmenopausal women. Current Therapeutic Research - Clinical and Experimental 1999;60(10):534-47. [DOI: ]
7. De Aloysio D, Rovati LC, Giacovelli G, Setnikar I, Bottiglioni F. Efficacy on climacteric symptoms and safety of low dose estradiol transdermal matrix patches. Azneimittelforschung 2000;50:293-300.
8. De Vrijer B, Snijders MP, Troostwijk AL, Thé RJ, Iding Da Freise JM, Smit H, et al. Efficacy and tolerability of a new estradiol delivering matrix patch (Estraderm MX) in postmenopausal women. Maturitas 2000;34:47-55.
9. Good WR, John VA, Ramirez M, Higgins JE. Comparison of Alora estradiol matrix transdermal delivery system with oral conjugated equine estrogen therapy in relieving menopausal symptoms. Climacteric 1999;2:29-36.
10. Gordon SF, Thompson KA, Ruoff GE, Imig JR, Lane PJ, Schwenker CE. Efficacy and safety of a seven-day, transdermal estradiol drug-delivery system: comparison with conjugated estrogens and placebo. International Journal of Fertility and Menopausal Studies 1995;40:126-34.
11. Haines C, Yu SL, Hiemeyer F, Schaefers M. Micro-dose transdermal estradiol for relief of hot flushes in postmenopausal Asian women: a randomized controlled trial. Climacteric 2009;12:419-26.
12. Honjo H, Taketani Y. Low-dose estradiol for climacteric symptoms in Japanese women: a randomized, controlled trial. Climacteric 2009;12:319-28. [DOI: 10.1080/13697130802657888]
13. Nielsen TF, Ravn P, Pitkin J, Christiansen C. Pulsed estrogen therapy improves postmenopausal quality of life: a 2-year placebo-controlled study. Maturitas 2006;53:184-90. [DOI: 10.1016]
14. Notelovitz M, Lenihan JP, McDermott M, Kerber IJ, Nanavati N, Arce J. Initial 17beta-estradiol dose for treating vasomotor symptoms. Menopause 2000;7:310-17.
15. Notelovitz M, Mattox JH. Suppression of vasomotor and vulvovaginal symptoms with continuous oral 17beta-estradiol. Menopause 2000;7:310-317.
16. Rovati LC, Setnikar I, Genazzani AR. Dose-response efficacy of a new estradiol transdermal matrix patch for 7-day application: a randomized, double-blind, placebo-controlled study. Menopause: The Journal of The North American Menopause Society 2002;22(1):114-21. [DOI: 10.1097]
17. Simon JA. Estradiol in micellar nanoparticles: the efficacy and safety of a novel transdermal drug-delivery technology in the management of moderate to severe vasomotor symptoms. Menopause: The Journal of The North American Menopause Society 2006;13(2):222-31. [DOI: 10.1097/01.gme.0000174096.56652.4f]
18. Simon JA, Bouchard C, Waldbaum A, Utian W, Zborowski J, Snabes MC. Low dose of transdermal estradiol gel for treatment of symptomatic postmenopausal women: a randomized controlled trial. Obstetrics and Gynecology 2007;109(3):588-96.
19. Speroff L, Whitcomb RW, Kempfert NJ, Boyd RA, Paulissen JB, Rowan JP. Efficacy and local tolerance of a low-dose, 7-day matrix estradiol transdermal system in the treatment of menopausal vasomotor symptoms. Obstetrics and Gynecology 1996;88(4):587-92.
20. Speroff L, Whitcomb RW, Kempfert NJ, Boyd RA, Paulissen JB, Rowan JP. Efficacy and local tolerance of a low-dose, 7-day matrix estradiol transdermal system in the treatment of menopausal vasomotor symptoms. Obstetrics and Gynecology 1996;88(4):587-92.
21. Utian WH, Burry KA, Archer DF. Efficacy and safety of low, standard, and high dosages of an estradiol transdermal system (Esclim) compared with placebo on vasomotor symptoms in highly symptomatic menopausal patients. American Journal of Obstetrics and Gynecology 1999;181:71-9.
22. von Holst T, Sallbach B. Efficacy and tolerability of a new 7-day transdermal estradiol patch versus placebo in hysterectomized women with postmenopausal complaints. Maturitas 2000;34:143-53.
23. Wiklund I, Karlberg J, Mattsson LA. Quality of life of postmenopausal women on a regimen of transdermal estradiol therapy: a double-blind placebo-controlled study. American Journal of Obstetrics and Gynecology 1993;168:824-30.
24. Akhila V, Pratapkumar A comparison of transdermal and oral HRT for menopausal symptom control. International Journal of Fertility and Women's Medicine 2006;51(2):64-9.
25. Bachmann GA. Estrogen no matter how delivered relieves postmenopausal vasomotor symptoms. Menopause 2003;10(6):494-6.
26. Bachmann GA, Schaefers M, Uddin A, Utian WH. Lowest effective transdermal 17-estradiol dose for relief of hot flushes in postmenopausal women. Obstetrics and Gynecology 2007;110(4):771-9.
27. Bachmann GA, Schaefers M, Uddin A, Utian WH. What's the lowest effective estrogen dose for hot flushes?. Journal of Family Practice 2008;57(1):9.
28. Ben-Chetrit A, Hochner-Celnikier D, Lindenberg T, Zacut D, Shimonovitz S, Gelber H, et al. Vaginal ring delivering estradiol and progesterone: a possible alternative to relieve climacteric symptoms. Israeli Medical Association Journal 2005;7:302-6.
29. Carranza-Lira S, Gooch AL, Velasco-Díaz G, Solano J, Arzola-Paniagua A. Low and ultra low-dose estrogen therapy for climacteric symptom control - preliminary report. International Journal of Fertility and Women's Medicine 2006;51(4):171-5.
30. Castelo-Branco C, Coloma JL. The role of intranasal estradiol spray in the management of moderate to severe vasomotor symptoms in menopausal women. Gynecological Endocrinology 2010;26(1):23-9. [DOI: 10.3109/09513590903159698]
31. Chung TKH, Yip SK, Lam P, Chang AMZ, Haines CJ. A randomized, double-blind, placebo-controlled, crossover study on the effect of oral oestradiol on acute menopausal symptoms. Maturitas 1996;25:115-23. [PUBMED: ]
32. Conaway E. Bioidentical hormones: an evidence-based review for primary care providers. Journal of the American Osteopathic Association 2011;111(3):153-64.
33. Cortés-Bonilla M, Bernardo-Escudero R, Alonso-Campero R, Francisco-Doce MT, Hernández-Valencia M, Celis-González C, et al. Treatment of menopausal symptoms with three low-dose continuous sequential 17β-estradiol/progesterone parenteral monthly formulations using novel non-polymeric microsphere technology. Gynecological Endocrinology 2015;10:1-8.
34. Darj E, Nilsson S, Axelsson O, Hellberg D. Clinical and endometrial effects of oestradiol and progesterone in post-menopausal women. Maturitas 1991;13(2):109-15.
35. Diem S, Grady D, Quan J, Vittinghoff E, Wallace R, Hanes V, et al. Effects of ultra low-dose transdermal estradiol on postmenopausal symptoms in women aged 60 to 80 years. Menopause 2006;13(1):130-8. [DOI: 10.1097/01.gme.0000192439.82491.24]
36. Ettinger B. Rationale for use of lower estrogen doses for postmenopausal hormone therapy. Maturitas 2007;57(1):81-4.
37. Files JA, Ko MG, Pruthi S. Bioidentical hormone therapy. Mayo Clinic Proceedings 2011;86(7):673.
38. Formby B, Schmidt F. Efficacy of biorhythmic transdermal combined hormone treatment in relieving climacteric symptoms: a pilot study. International Journal of General Medicine 2011;4:159-63.
39. Ganz P. Vasomotor and vascular effects of hormone replacement therapy. American Journal of Cardiology 2002;90:F11-16. [PUBMED: 12106634]
40. Gass MS, Rebar RW, Cuffie-Jackson C, Cedars MI, Loboe RA, Shoupe D, et al. A short study in the treatment of hot flashes with buccal administration of 17- estradiol. Maturitas 2004;49:140-7.
41. Hedrick RE, Ackerman RT, Koltun WD, Halvorsen MB, Lambrecht LJ. Transdermal estradiol gel 0.1% for the treatment of vasomotor symptoms in postmenopausal women. The Journal of The North American Menopause Society 2009;16(1):132-40. [DOI: 10.1097/gme.0b013e31817d5372]
42. Iftikhar S, Shuster LT, Johnson RE, Jenkins SM, Wahner-Roedler DL. Use of bioidentical compounded hormones for menopausal concerns: cross-sectional survey in an academic menopause center. Journal of Women's Health 2011;20(4):559-65. [DOI: 10.1089]
43. Jensen PB. Climacteric symptoms after oral and percutaneous hormone replacement therapy. Maturitas 1987;9:207-15.
44. Lacut K, et al. Effects of oral and transdermal 17 beta-estradiol combined with progesterone on homocysteine metabolism in postmenopausal women: a randomised placebo-controlled trial. Atherosclerosis 2004;174(1):173-80. [PUBMED: 15135267]
45. Lindh-Åstrand L, Nedstrand E, Wyon Y, Hammar M. Vasomotor symptoms and quality of life in previously sedentary postmenopausal women randomised to physical activity or estrogen therapy. Maturitas 2003;48:97-105.
46. Lopes P, Merkus HM, Nauman J, Bruschi F, Foidart JM, Calaf J. Randomized comparison of intranasal and transdermal estradiol. Obstetrics and Gynecology 2000;96(6):906-12.
47. Lübbert H, Nauert C. Continuous versus cyclical transdermal estrogen replacement therapy in postmenopausal women: influence on climacteric symptoms, body weight and bleeding pattern. Maturitas 1997;28:117-25.
48. MacLennan AH. Evidence-based review of therapies at the menopause. International Journal of Evidence Based Healthcare 2009;7:112-23. [DOI: 10.1111]
49. Marslew U, Riis B, Christiansen C. Progestogens: therapeutic and adverse effects in early post-menopausal women. Maturitas 1991;13(1):7-16.
50. Marslew U, Munk-Nielsen N, Nilas L, Riis BJ, Christiansen C. Bleeding pattern and climacteric symptoms during different sequential combined HRT regimens in current use. Maturitas 1994;19(3):225-37.
51. Mather KJ, Norman EG, Prior JC, Elliott TG. Preserved forearm endothelial responses with acute exposure to progesterone: a randomized cross-over trial of 17-b estradiol, progesterone, and 17-b estradiol with progesterone in healthy menopausal women. The Journal of Clinical Endocrinology and Metabolism 2000;85(12):4644-49.
52. Mirkin S, Amadio JM, Bernick BA, Pickar JH, Archer DF. 17(beta)-Estradiol and natural progesterone for menopausal hormone therapy: REPLENISH phase 3 study design of a combination capsule and evidence review. Maturitas 2015;81(1):28-35.
53. Mizunuma H. Clinical usefulness of a low-dose maintenance therapy with transdermal estradiol gel in Japanese women with estrogen deficiency symptoms. Climacteric 2011;14:581-89. [CENTRAL: CN-00806509; ]
54. Odabaşi AR, Yüksel H, Demircan SS, Kaçar DF, Çulhaci N, Özkara EE. A prospective randomized comparative study of the effects of intranasal and transdermal 17ß estradiol on postmenopausal symptoms and vaginal cytology. Journal of Postgraduate Medicine 2007;53:221-7.
55. Panay N, Ylikorkala O, Archer DF, Gut R, Lang E. Ultra-low-dose estradiol and norethisterone acetate: effective menopausal symptom relief. Climacteric 2007;10:120-31.
56. Pélissier C, Maroni M, Yaneva H, Brin S, Peltier-Pujol F, Jondet M. Chlormadinone acetate versus micronized progesterone in the sequential combined hormone replacement therapy of the menopause. Maturitas 2001;40(1):85-94.
57. Rosano GMC, Webb CM, Chierchia S, Morgani GL, Gabraele M, Sarrel PM, et al. Natural progesterone, but not medroxyprogesterone acetate, enhances the beneficial effect of estrogen on exercise-induced myocardial ischemia in postmenopausal women. Journal of the American College of Cardiology 2000;36(7):2154-9.
58. Ryan N, Rosner A. Quality of life and costs associated with micronized progesterone and medroxyprogesterone acetate in hormone replacement therapy for nonhysterectomized, postmenopausal women. Clinical Therapeutics 2001;23(7):1099-1115. [DOI: 10.1016]
59. Serfaty D, Reilhac P, Eschwege E, Ringa V, Blin P, Nandeuil A, et al. Compliance with hormone replacement therapy in menopausal women: results of a two-year prospective French study comparing transdermal treatment with fixed oral combination therapy [Observance du traitement hormonal substitutif de la ménopause: résultats d'une étude prospective française de deux ans, comparantun traitement transdermique et une association fixe par voie orale]. Gynécologie Obstétrique and Fertilité 2003;31:525-33.
60. Sitruk-Ware R. Routes of delivery for progesterone and progestins. Maturitas 2007;57:77-80.
61. Siyam T, Yuksel N. Beliefs about bioidentical hormone therapy: a cross-sectional survey of pharmacists. Maturitas 2013;74:196-202.
62. Skarsgard C, Berg GE, Ekblad S, Wiklund I, Hammar ML. Effects of estrogen therapy on well-being in postmenopausal women without vasomotor complaints. Maturitas 2000;36:123-30.
63. Somunkiran A, Erel CT, Demirci F, Senturk ML. The effect of tibolone versus 17-estradiol on climacteric symptoms in women with surgical menopause: a randomized, cross-over study. Maturitas 2007;56:61-8.
64. Sood R, Shuster L, Smith R, Vincent A, Jatoi A. Counseling postmenopausal women about bioidentical hormones: ten discussion points for practicing physicians. Journal of the American Board of Family Medicine 2011;24(2):202-10.
65. Sood R, Warndahl RA, Schroeder DR, Singhd R J, Rhodes DJ, Wahner-Roedlerf D, et al. Bioidentical compounded hormones: a pharmacokinetic evaluation in a randomized clinical trial. Maturitas 2013;74:375- 82.
66. Studd J, Pornel B, Marton I, Bringer J, Varin C, Tsouderos Y, et al. Efficacy and acceptability of intranasal 17 -oestradiol for menopausal symptoms: randomised dose-response study. Lancet 1999;353:1574-8.
67. Suvanto-Luukkonen E, Sundstrijm E, Jorma Penttinen J, Läärä E, Pramila S, Kauppila A. Percutaneous estradiol gel with an intrauterine levonorgestrel releasing device or natural progesterone in hormone replacement therapy. Maturitas 1997;26:211-17.
68. Vartiainen J, Wahlstriim T, Nilsson CG. Effects and acceptability of a new 17B-oestradiol releasing vaginal ring in the treatment of postmenopausal complaints. Maturitas 1993;17:129-37.
69. Veerus P, Hovi SL, Sevón T, Hunter M, Hemminki E. The effect of hormone therapy on women's quality of life in the first year of the Estonian Postmenopausal Hormone Therapy trial. Menopause 2013;20(3):291-8. [DOI: 10.1097/GME.0b013e31826ce3ed.]
70. Whelan AM, Jurgens TM, Trinacty M. Bioidentical progesterone cream for menopause-related vasomotor symptoms: is it effective?. The Annals of Pharmacotherapy 2013;47:112-6. [DOI: 10.1345]
71. Wihlbäck A, Nyberg S, Bäckström T, Bixo M, Sundstrom-Poromaa I. Estradiol and the addition of progesterone increase the sensitivity to a neurosteroid in postmenopausal women. Psychoneuroendocrinology 2005;30(1):38-50.
72. Wolfe BM, Plunkettb ER. Early effects of continuous low-dosage dl-norgestrel administered alone or with estrogen. Maturitas 1994;18:207-19.
73. Yesildaglar N, Erkaya S, Uygur D, Göl K, Bingöl B, Günenç Z. Efficacy of pulsed estrogen therapy in relatively younger patients with surgically induced menopause. Human Reproduction 2004;19(1):210-3.
74. Adams C, Cannell S. Women's beliefs about "natural" hormones and natural hormone replacement therapy. Menopause 2001;8:433-40.
75. Cagnacci A, Arangino S, Tuveri F, Paoletti AM, Volpe A. Regulation of the 24h body temperature rhythm of women in luteal phase: role of gonadal steroids and prostaglandins. Chronobiology International Journal 2002;19(4):721-30.
76. Corbelli J, Shaikh N, Wessel C, Hess R. Low-dose transdermal estradiol for vasomotor symptoms: a systematic review. Menopause: The Journal of The North American Menopause Society 2014;22(1):114-21. [DOI: 10.1097/gme.0000000000000258]
77. Corson SL. A decade of experience with transdermal estrogen replacement therapy: overview of key pharmacologic and clinical findings. International Journal of Fertility 1993;38:79-81.
78. Deeks JJ, Higgins JPT, Altman DG (editors). Chapter 9: Analysing data and undertaking meta-analyses. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
79. Drisko JA. Natural isomolecular hormone replacement: an evidence-based medicine approach. International Journal of Pharmaceutical Compounding 2000;4:414-20.
80. European Medicines Agency. Guideline on clinical investigation of medicinal products for hormone replacement therapy of oestrogen deficiency symptoms in postmenopausal women. ema.europa.eu/ema/ Accessed September 2012.
81. Endocrine Society. Bioidentical hormones: position statement. endo-society.org/advocacy/policy/upload/BH_position_Statement_final_10_25_06_w_Header.pdf Accessed May 20, 2012.
82. US Department of Health and Human Services. Guidance for industry: estrogen and estrogen/progestin drug products to treat vasomotor symptoms and vulvar and vaginal atrophy symptoms-recommendations for clinical evaluation. fda.gov/cder/guidance/index.htm January 2003. [fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm071643.pdf(accessed 2014 july) ]
83. Freedman RR. Physiology of hot flashes. American Journal of Human Biology 2001;13:453.
84. Freedman RR, Benton MD, Genik II RJ, Graydon FX. Cortical activation during menopausal hot flashes. Fertility and Sterility 2006;85:674.
85. Furness S, Roberts H, Marjoribanks J, Lethaby A. Hormone therapy in postmenopausal women and risk of endometrial hyperplasia. Cochrane Database of Systematic Reviews 2012, Issue 8. [DOI: 10.1002/14651858; CD000402]
86. McMaster University (developed by Evidence Prime, Inc). Available from gradepro.org. GRADEpro Guideline Development Tool. McMaster University (developed by Evidence Prime, Inc). Available from gradepro.org, 2015.
87. Harlow SD, Gass M, Hall JE, Lobo R, Maki P, Rebar RW, et al. Executive summary of the Stages of Reproductive Aging Workshop D10: addressing the unfinished agenda of staging reproductive aging. Journal of Clinical Endocrinology and Metabolism 2012;97(4):1159-68.
88. Heidi DN. Commonly used types of postmenopausal estrogen for treatment of hot flashes. JAMA 2004;219(13):1610-20. [DOI: 10.1001/jama.291.13.1610]
89. Hersh AL, Stefanick ML, Stafford RS. National use of postmenopausal hormone therapy: annual trends and response to recent evidence. JAMA 2004;291:47-53.
90. Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003;327:557-60.
91. Higgins JPT, Altman DG, Sterne JAC (editors). Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
92. Higgins JPT, Deeks JJ, Altman DG (editors). Chapter 16: Special topics in statistics. In: Higgins JPT, Green S (editors), Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
93. Hilditch JR, Lewis J, Peter A, Van Maris B, Ross A, Franssen E, et al. A menopause-specific quality of life questionnaire: development and psychometric properties. Maturitas 1996;24(3):161-75.
94. Hunter MS. Women's Health Questionnaire: a measure of mid-aged women's perceptions of their emotional and physical health. Psychology and Health 1992;7(1):45-54.
95. Kaufert P, Boggs PP, Ettinger B, Woods NF, Utian WH. Women and menopause: beliefs, attitudes, and behaviours. Menopause 1998;5:197.
96. Kopper NW, Gudeman J, Thompson DJ. Transdermal hormone therapy in postmenopausal women: a review of metabolic effects and drug delivery technologies. Journal of Drug Design Development and Therapy 2009;6(2):193-202. [PUBMED: 19920906 ]
97. Kronnenberg F, Barnard RM. Modulation of menopausal hot flashes by ambient temperature. Journal of Thermal Biology 1992;17:43.
98. Lethaby A, Marjoribanks J, Kronenberg F, Roberts H, Eden J, Brown J. Phytoestrogens for menopausal vasomotor symptoms. The Cochrane Library 2013;12:CD001395. [DOI: 10.1002/14651858]
99. North American Menopause Society. Hormone therapy position statement of The North American Menopause Society. The Journal of The North American Menopause Society 2012;19(3):257-71.
100. Nelson HD, Vesco KK, Haney E, Fu R, Nedrow A, Miller J, et al. Nonhormonal therapies for menopausal hot flashes: systematic review and meta-analysis. JAMA 2006;295(17):2057-69.
101. Nielsen TF, Ravn P, Bagger YZ, Warming L, Christiansen C. Pulsed estrogen therapy in prevention of postmenopausal osteoporosis. A 2-year randomized, double blind, placebo-controlled study. Osteoporosis International 2004;15(2):168-74.
102. The Nordic Cochrane Centre, Cochrane. Review Manager (RevMan). Version 5.3. Copenhagen: The Nordic Cochrane Centre, Cochrane, 2014.
103. Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, et al. Risks and benefits of estrogen plus progestin for healthy postmenopausal women. JAMA 2002;288:321-33.
104. Rossouw JE, Manson JE, Kaunitz AM, Anderson GL. Lessons learned from the Women's Health Initiative trials of menopausal hormone therapy. Obstetrics and Gynecology 2013;121(1):172-6.
105. Seidl MM, Stewart DE. Alternative treatments for menopausal symptoms: qualitative study of women's experiences. Canadian Family Physician 1998;44:1271-6.
106. Shifren JL, Desindes S, McIlwain M, Doros G, Mazer NA. A randomised, open-label, crossover study comparing the effects of oral versus transdermal estrogens therapy on serum androgens, thyroid hormones, and adrenal hormones in naturally menopausal women. Menopause 2007;14:985.
107. Shifren JL, Schiff I. Role of hormone therapy in the management of menopause. Obstetrics and Gynecology 2010;115(4):839-55.
108. Speroff L, Glass RH, Kase NG, editors. Clinical Gynecologic Endocrinology and Infertility. Clinical Gynecologic Endocrinology and Infertility. 8th Edition. Philadelphia, PA: Lippincott Williams & Wilkins, 2011.
109. Steingold KA, Matt DW, DeZiegler D, Sealey JE, Fratkin M, Reznikov S. Comparison of transdermal to oral estradiol administration on hormonal and hepatic parameters in women with premature ovarian failure. Journal of Clinical Endocrinology and Metabolism 1991;73:275-80.
110. Sturdee DW, Pines A, on behalf of the International Menopause Society Writing Group. Updated IMS recommendations on postmenopausal hormone therapy and preventive strategies for midlife health. Climacteric 2011;14:202-20.
111. Tartaryn IV, Lomax P, Meldrum DR, Bajorek JG, CHesorek W, Judd HL. Objective techniques for the assessment of menopausal hot flushes. Obstetrics and Gynecology 1981;57:340-4.
112. Wilkin JR. Flushing reactions: consequences and mechanisms. Annals of Internal Medicine 1981;95:468.
113. Gaudard AMIS, da Silva EMK, Silva de Souza S, Torloni MR, Macedo CR. Bioidentical hormones for women with hot flushes. Cochrane Database of Systematic Reviews 2013, Issue 2. [DOI: 10.1002/14651858.CD010407]